Forlenza CJ, Rosenzweig J, Mauguen A, et al. Brentuximab Vedotin Following Autologous Transplantation in Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood Advances. 2023; (doi: 10.1182/bloodadvances.2022009323).

Researchers report that among children with relapsed and refractory Hodgkin lymphoma (HL), brentuximab vedotin was well tolerated following autologous stem cell transplant, suggesting the anti-CD30 antibody-drug conjugate's viability as a post-transplant consolidation therapy. With few pediatric patients with relapsed/refractory HL treated with brentuximab vedotin represented in medical literature, the 67 patients in this retrospective analysis represent the largest such cohort to date. The 3-year progression-free survival rate was 85%, with a median follow up of 37 months. Brentuximab vedotin consolidation in this pediatric population also had a favorable safety profile, one that was similar to that for adult patients.

Read More

Tags: children, Refractory, Lymphoma, HLA, results, Resource